Currency In USD
| Previous Close | 11.73 |
| Open | 11.5 |
| Day High | 11.62 |
| Day Low | 11.1 |
| 52-Week High | 16.44 |
| 52-Week Low | 6.23 |
| Volume | 1.07M |
| Average Volume | 2.7M |
| Market Cap | 2.43B |
| PE | -7.82 |
| EPS | -1.42 |
| Moving Average 50 Days | 9.41 |
| Moving Average 200 Days | 9.97 |
| Change | -0.63 |
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Mar 09, 2026 8:01 PM GMT
BEDFORD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to th
Ocular Therapeutix™ to Participate in March Investor Conferences
GlobeNewswire Inc.
Feb 24, 2026 12:00 PM GMT
BEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in several
Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations
GlobeNewswire Inc.
Feb 23, 2026 12:00 PM GMT
Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET) Company to host an investor webcast on Monday, March 2, 2026, at 7:30 AM ET to discuss the Macula Societ